|Articles|January 30, 2019

Payer and Specialty Pharmacy Forum: Von Willebrand Disease Management Including a Patient Perspective

https://www.pharmacytimes.org/on-demand/american-journal-of-managed-care-payer-and-specialty-pharmacy-forum-von-willebrand-disease-management-including-a-patient-perspective

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Patients spoke of navigating unwritten social rules around who could know about their hair loss and when concealment was expected. | Image credit: Creative Cat Studio - stock.adobe.com

Exploring Identity, Appearance Experiences Among Patients With Alopecia

ByAJMC Contributor

February 6th 2026

pill with water -New Africa - stock.adobe.com

5 Things to Know About the Oral GLP-1 Era

ByGiuliana Grossi

February 6th 2026

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

ByMary Caffrey

February 6th 2026

The mechanistic role of HP in CSU remains unclear, and whether HP is merely a marker of inflammation or an active contributor to disease processes warrants further investigation. | Image Credit: stock.adobe.com

Potential Predictor of Treatment Response in Chronic Spontaneous Urticaria Identified

ByAJMC Contributor

February 6th 2026

Acalabrutinib | Image Credit: © Сергей Шиманович-stocka.dobe.com.jpeg

Real-World Evidence Backs Acalabrutinib in CLL Care

ByMaggie L. Shaw

February 6th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Payer and Specialty Pharmacy Forum: Von Willebrand Disease Management Including a Patient Perspective

Newsletter

Related Content

Exploring Identity, Appearance Experiences Among Patients With Alopecia

5 Things to Know About the Oral GLP-1 Era

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

Potential Predictor of Treatment Response in Chronic Spontaneous Urticaria Identified

Real-World Evidence Backs Acalabrutinib in CLL Care

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era